The Efficacy of Ursodeoxycholic acid (UDCA) on Liver Regeneration After Major HepatectomyThe Efficacy of Ursodeoxycholic acid (UDCA) on Liver Regeneration After Major Hepatectomy

Phase 4

• Conditions: Patients that are scheduled for elective major hepatectomy due to liver tumors; Major hepatectomy, Ursodeoxycholic acid (UDCA), Liver regeneration

• Registration Number: TCTR20210831003
• Lead Sponsor: Research Fund of Faculty of Medicine, Chiang Mai University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-08-31
• Last Update Posted: 19 August 2024
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Age over 18 years
2. Elective major hepatectomy due to liver tumors
3. ICG R-15 less than 10%
Obstructive jaundice case: TB < 3 mg/dL
4.Written informed consent

Exclusion Criteria

1. Presence of medical conditions putting the individual patient at increased risk for not tolerating hepatic resection
- Liver cirrhosis Child-Pugh B or C
- ICG-R 15 more than 10%
- Platelet less than 150,000 cells/cu.mm
- Coagulopathy: INR > 1.5
2. Hypersensitivity to Ursodeoxycholic acid (UDCA)
3. Hypersensitivity to contrast media
4. Participation in other clinical trials or observation period of competing trials interfering with the endpoints of this trial
5. Suspected lack of compliance
6. Impaired mental status or language problems
7. Refusal to take part in the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
liver regeneration 3 month 1. liver volume measurement from CT scan 2. Proinflammatory cytokines level 3. Histochemistry measurement

Secondary Outcome Measures

Name	Time	Method
Post-hepatectomy liver failure 30 days Number of events (PHLF, 30-day mortality)